Cetylpyridinium Chloride (CPC) Exhibits Potent, Rapid Activity Against Influenza Viruses in vitro and in vivo
Article Sidebar
Main Article Content
Abstract
Background: There is a continued need for strategies to prevent influenza. While cetylpyridinium chloride (CPC), a broad-spectrum antimicrobial agent, has an extensive antimicrobial spectrum, its ability to affect respiratory viruses has not been studied in detail.
Objectives: Here, we evaluate the ability of CPC to disrupt influenza viruses in vitro and in vivo.
Methods: The virucidal activity of CPC was evaluated against susceptible and oseltamivir- resistant strains of influenza viruses. The effective virucidal concentration (EC) of CPC was determined using a hemagglutination assay and tissue culture infective dose assay. The effect of CPC on viral envelope morphology and ultrastructure was evaluated using transmission electron microscopy (TEM). The ability of influenza virus to develop resistance was evaluated after multiple passaging in sub-inhibitory concentrations of CPC. Finally, the efficacy of CPC in formulation to prevent and treat influenza infection was evaluated using the PR8 murine influenza model.
Results: The virucidal effect of CPC occurred within 10 minutes, with mean EC50 and EC2log ranging between 5 to 20 µg/mL, for most strains of influenza tested regardless of type and resistance to oseltamivir. Examinations using TEM showed that CPC disrupted the integrity of the viral envelope and its morphology. Influenza viruses demonstrated no resistance to CPC despite prolonged exposure. Treated mice exhibited significantly increased survival and maintained body weight compared to untreated mice.
Conclusions: The antimicrobial agent CPC possesses virucidal activity against susceptible and resistant strains of influenza virus by targeting and disrupting the viral envelope. Substantial virucidal activity is seen even at very low concentrations of CPC without development of resistance. Moreover, CPC in formulation reduces influenza-associated mortality and morbidity in vivo.
Keywords: Cetylpyridinium Chloride, CPC, Influenza, Respiratory tract illness, respiratory virus, quaternary ammonium compound
Downloads
Article Details
Pathogens and Immunity abides by Creative Commons BY 4.0:
http://creativecommons.org/licenses/by/4.0/
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
References
1. Bosch AA, Biesbroek G, Trzcinski K, Sanders EA, Bogaert D. Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog. 2013;9(1):e1003057. PubMed PMID: 23326226. Pubmed Central PMCID: 3542149. doi: 10.1371/journal.ppat.1003057
2. Dasaraju PV, Liu C. Infections of the Respiratory System. 2011/03/18 ed1996.
3. Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, McGeer AJ, Neuzil KM, Pavia AT, Tapper ML, Uyeki TM, Zimmerman RK. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(8):1003-32. PubMed PMID: 19281331. doi: 10.1086/598513
4. Jacobs SE, Lamson DM, St George K, Walsh TJ. Human rhinoviruses. Clin Microbiol Rev. 2013;26(1):135-62. PubMed PMID: 23297263. Pubmed Central PMCID: 3553670. doi: 10.1128/CMR.00077-12
5. West JV. Acute upper airway infections. Br Med Bull. 2002;61:215-30. PubMed PMID: 11997308.
6. (WHO) WHO. Influenza (Seasonal) 2014. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/
7. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086-96. PubMed PMID: 17544181. doi: 10.1016/j.vaccine.2007.03.046
8. Centers for Disease Control and Prevention (CDC). Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. 2011;60(7 (RR-1)):1-24.
9. Glezen WP. Prevention and Treatment of Seasonal Influenza. New England Journal of Medicine. 2008;359(24):2579-85. PubMed PMID: 19073977. doi: 10.1056/NEJMcp0807498
10. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, Centers for Disease C, Prevention. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1-24. PubMed PMID: 21248682.
11. Burch J, Paulden M, Conti S, Stock C, Corbett M, Welton NJ, Ades AE, Sutton A, Cooper N, Elliot AJ, Nicholson K, Duffy S, McKenna C, Stewart L, Westwood M, Palmer S. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess. 2009;13(58):1-265, iii-iv. PubMed PMID: 19954682. doi: 10.3310/hta13580
12. Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, Thompson MJ. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012;1:CD008965. PubMed PMID: 22258996. doi: 10.1002/14651858.CD008965.pub3
13. Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One. 2013;8(4):e60348. PubMed PMID: 23565231. Pubmed Central PMCID: 3614893. doi: 10.1371/journal.pone.0060348
14. Hoffman KB, Demakas A, Erdman CB, Dimbil M, Doraiswamy PM. Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012. BMJ. 2013;347:f4656. PubMed PMID: 23881998.
15. Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, Zhang X, Yen HL, Shi B, Li T, Guan W, Xu L, Liu Y, Wang S, Zhang X, Tian D, Zhu Z, He J, Huang K, Chen H, Zheng L, Li X, Ping J, Kang B, Xi X, Zha L, Li Y, Zhang Z, Peiris M, Yuan Z. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet. 2013;381(9885):2273-9. PubMed PMID: 23726392. doi: 10.1016/S0140-6736(13)61125-3
16. Jefferson T, Jones M, Doshi P, Del Mar C. Possible harms of oseltamivir--a call for urgent action. Lancet. 2009;374(9698):1312-3. PubMed PMID: 19837238. doi: 10.1016/S0140-6736(09)61804-3
17. Lu PJ, Santibanez TA, Williams WW, Zhang J, Ding H, Bryan L, O'Halloran A, Greby SM, Bridges CB, Graitcer SB, Kennedy ED, Lindley MC, Ahluwalia IB, LaVail K, Pabst LJ, Harris L, Vogt T, Town M, Singleton JA, Centers for Disease C, Prevention. Surveillance of influenza vaccination coverage--United States, 2007-08 through 2011-12 influenza seasons. MMWR Surveill Summ. 2013;62(4):1-28. PubMed PMID: 24157710.
18. (CDC) CfDCaP. FluVaxVIew 2016. Available from: http://www.cdc.gov/flu/fluvaxview/
19. Demicheli V, Jefferson T, Al-Ansary LA, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2014;3:CD001269. PubMed PMID: 24623315. doi: 10.1002/14651858.CD001269.pub5
20. Flannery B, Thaker SN, Clippard J, Monto AS, Ohmit SE, Zimmerman RK, Nowalk MP, Gaglani M, Jackson ML, Jackson LA, Belongia EA, McLean HQ, Berman L, Foust A, Sessions W, Spencer S, Fry AM. Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, february 2014. MMWR Morb Mortal Wkly Rep. 2014;63(7):137-42. PubMed PMID: 24553196.
21. Lu PJ, Santibanez TA, Williams WW, Zhang J, Ding H, Bryan L, O'Halloran A, Greby SM, Bridges CB, Graitcer SB, Kennedy ED, Lindley MC, Ahluwalia IB, LaVail K, Pabst LJ, Harris L, Vogt T, Town M, Singleton JA. Surveillance of influenza vaccination coverage--United States, 2007-08 through 2011-12 influenza seasons. MMWR Surveill Summ. 2013;62(4):1-28. PubMed PMID: 24157710.
22. Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, Karron RA, Jernigan DB, Bresee JS. Prevention and Control of Seasonal Influenza with Vaccines. MMWR Recomm Rep. 2016;65(5):1-54. PubMed PMID: 27560619. doi: 10.15585/mmwr.rr6505a1
23. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9(8):493-504. PubMed PMID: 19628174. Pubmed Central PMCID: 2775097. doi: 10.1016/S1473-3099(09)70175-6
24. Committee on Infectious Diseases AAoP. Recommendations for Prevention and Control of Influenza in Children, 2015-2016. Pediatrics. 2015;136(4):792-808. PubMed PMID: 26347430. doi: 10.1542/peds.2015-2920
25. Association BIBR. Toxicity Profile for Cetylpyridinium chloride 2005. Available from: http://www.bibra-information.co.uk/downloads/toxicity-profile-for-cetylpyridinium-chloride-2005/
26. Busscher HJ, White DJ, Atema-Smit J, Geertsema-Doornbusch G, de Vries J, van der Mei HC. Surfactive and antibacterial activity of cetylpyridinium chloride formulations in vitro and in vivo. J Clin Periodontol. 2008;35(6):547-54. PubMed PMID: 18384389. doi: 10.1111/j.1600-051X.2008.01230.x
27. Pitten FA, Kramer A. Efficacy of cetylpyridinium chloride used as oropharyngeal antiseptic. Arzneimittelforschung. 2001;51(7):588-95. PubMed PMID: 11505791. doi: 10.1055/s-0031-1300084
28. Federal Register Volume 59, Issue 27 (February 9, 1994). Office of the Federal Register, National Archives and Records Administration; 1994. p. 6093 - 4.
29. Gilbert P, Moore LE. Cationic antiseptics: diversity of action under a common epithet. J Appl Microbiol. 2005;99(4):703-15. PubMed PMID: 16162221. doi: 10.1111/j.1365-2672.2005.02664.x
30. Repetto G, del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc. 2008;3(7):1125-31. PubMed PMID: 18600217. doi: 10.1038/nprot.2008.75
31. Eisfeld AJ, Neumann G, Kawaoka Y. Influenza A virus isolation, culture and identification. Nat Protoc. 2014;9(11):2663-81. PubMed PMID: 25321410. doi: 10.1038/nprot.2014.180
32. Szretter KJ, Balish AL, Katz JM. Influenza: propagation, quantification, and storage. Curr Protoc Microbiol. 2006;Chapter 15:Unit 15G 1. PubMed PMID: 18770580. doi: 10.1002/0471729256.mc15g01s3
33. Press A, editor. Virological Methods: ASM Press; 2009.
34. Mukherjee PK, Esper F, Buchheit K, Arters K, Adkins I, Ghannoum MA, Salata RA. Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections. BMC Infect Dis. 2017;17(1):74. PubMed PMID: 28088167. Pubmed Central PMCID: PMC5237564. doi: 10.1186/s12879-016-2177-8
35. Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am. 2010;24(2):413-37. PubMed PMID: 20466277. Pubmed Central PMCID: PMC2871161. doi: 10.1016/j.idc.2010.01.001
36. Blazejewska P, Koscinski L, Viegas N, Anhlan D, Ludwig S, Schughart K. Pathogenicity of different PR8 influenza A virus variants in mice is determined by both viral and host factors. Virology. 2011;412(1):36-45. PubMed PMID: 21256531. doi: 10.1016/j.virol.2010.12.047
37. Carmona-Ribeiro AM, de Melo Carrasco LD. Cationic antimicrobial polymers and their assemblies. Int J Mol Sci. 2013;14(5):9906-46. PubMed PMID: 23665898. Pubmed Central PMCID: 3676821. doi: 10.3390/ijms14059906
38. Maillard JY. Bacterial target sites for biocide action. J Appl Microbiol. 2002;92 Suppl:16S-27S. PubMed PMID: 12000609.
39. Ivanova PT, Myers DS, Milne SB, McClaren JL, Thomas PG, Brown HA. Lipid composition of viral envelope of three strains of influenza virus - not all viruses are created equal. ACS Infect Dis. 2015;1(9):399-452. PubMed PMID: 26448476. Pubmed Central PMCID: 4593503. doi: 10.1021/acsinfecdis.5b00040
40. Maillard JY, Hann AC, Beggs TS, Day MJ, Hudson RA, Russell AD. Electronmicroscopic investigation of the effects of biocides on Pseudomonas aeruginosa PAO bacteriophage F116. J Med Microbiol. 1995;42(6):415-20. PubMed PMID: 7791206. doi: 10.1099/00222615-42-6-415
41. McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses. 2013;7 Suppl 1:25-36. PubMed PMID: 23279894. 10.1111/irv.12047
42. Renzette N, Caffrey DR, Zeldovich KB, Liu P, Gallagher GR, Aiello D, Porter AJ, Kurt-Jones EA, Bolon DN, Poh YP, Jensen JD, Schiffer CA, Kowalik TF, Finberg RW, Wang JP. Evolution of the influenza A virus genome during development of oseltamivir resistance in vitro. J Virol. 2014;88(1):272-81. PubMed PMID: 24155392. Pubmed Central PMCID: 3911755. 10.1128/JVI.01067-13
43. Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother. 2009;53(10):4433-40. PubMed PMID: 19651908. Pubmed Central PMCID: 2764219. 10.1128/AAC.00334-09
44. Pizzorno A, Bouhy X, Abed Y, Boivin G. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis. 2011;203(1):25- 31. PubMed PMID: 21148493. Pubmed Central PMCID: 3086433. 10.1093/infdis/jiq010